Glenmark Pharmaceuticals Schedules Q3FY26 Results Earnings Call for February 02, 2026

Glenmark Pharmaceuticals Limited has announced its quarterly earnings call to discuss Q3FY26 financial results, scheduled for Monday, February 02, 2026. The pharmaceutical company has formally notified stock exchanges BSE and NSE about this investor communication event under regulatory compliance requirements.

Earnings Call Schedule and Access Details

The Q3FY26 results discussion will be conducted as a conference call with specific timing and access arrangements for investors and analysts.

Parameter:	Details
Date:	Monday, February 02, 2026
Time:	8:30 AM – 9:30 AM (IST)
Duration:	1 Hour
Format:	Conference Call

Global Dial-in Access Numbers

The company has provided multiple international access numbers to accommodate global investor participation:

Region:	Dial-in Number
India (Universal):	+91 22 6280 1298
India (Alternative):	+91 22 7115 8199
USA:	1 866 746 2133
UK:	0 808 101 1573
Singapore:	800 101 2045
Hong Kong:	800 964 448

Registration and Contact Information

Participants can pre-register online through the company's designated registration portal. For any clarifications regarding the earnings call, investors can contact Utkarsh Gandhi at utkarsh.gandhi3@glenmarkpharma.com or phone +91 22 4018 9232.

Regulatory Compliance and Recording

The earnings call announcement was made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Harish Kuber signed the official communication to both stock exchanges on January 22, 2026. The company has confirmed that the complete recording of the earnings call will be available on its official website within 24 hours of the call's completion, ensuring accessibility for stakeholders who cannot participate in the live session.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.87%	-0.70%	+0.26%	-8.59%	+33.19%	+301.73%

Glenmark Pharmaceuticals Inc., USA has announced the launch of Epinephrine Injection USP, 30mg/30mL (1mg/mL) Multiple-Dose Vial. This strategic product launch expands the company's portfolio within the institutional channel and targets a market worth approximately $67.60 million annually.

Product Details and Market Positioning

The newly launched Epinephrine Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 30mg/30mL (1mg/mL) of BPI Labs, LLC, NDA 205029. This ensures that patients receive the same therapeutic benefits as the original formulation while potentially benefiting from more competitive pricing.

Parameter:	Details
Product Name:	Epinephrine Injection USP
Strength:	30mg/30mL (1mg/mL)
Formulation:	Multiple-Dose Vial
Reference Drug:	BPI Labs, LLC (NDA 205029)
Market Size:	$67.60 million annually

Market Opportunity and Financial Impact

According to IQVIA sales data, the Epinephrine Injection USP, 30mg/30mL (1mg/mL) market achieved annual sales of approximately $67.60 million. This represents a significant market opportunity for Glenmark Pharmaceuticals as it seeks to capture market share in this established therapeutic segment.

Management Commentary

Marc Kikuchi, President Business Head, North America, expressed enthusiasm about the launch, stating that the company is excited to announce the launch of Epinephrine Injection USP, 30mg/30mL (1mg/mL) Multiple-Dose Vial. He emphasized that this launch grows their portfolio of products within the institutional channel while strengthening their commitment to bringing quality and affordable alternatives to market for patients.

Regulatory and Compliance Information

Glenmark's Epinephrine Injection USP, 30mg/30mL (1mg/mL) Multiple-Dose Vial is approved only for the indications listed in Glenmark's approved label. The company has ensured full regulatory compliance before bringing this product to market, maintaining its standards for quality and safety in pharmaceutical manufacturing.